Form 4: Core Scientific Insider Sells Shares Under 10b5-1 Plan

Todd DuChene, Chief Legal and Administrative Officer of Core Scientific, Inc., reported the sale of 9,900 shares of common stock for $28.1875 each, executed under a pre-arranged trading plan.

Summary

• Todd DuChene, Chief Legal and Administrative Officer of Core Scientific, Inc., sold 9,900 shares of common stock on June 15, 2026.
• The sale was conducted at a weighted average price of $28.1875 per share, with individual transactions ranging from $27.64 to $28.54.
• An additional 100 shares were sold at $28.79.
• These transactions were executed as part of a Rule 10b5-1 trading plan adopted on December 5, 2025.
• Following these sales, DuChene beneficially owns 2,058,895 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported transactions were conducted under a pre-arranged trading plan, mitigating concerns about opportunistic insider selling.

Negatives

• Insider selling can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established trading plan.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it solely reports on past transactions.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.64 to $28.54, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common and are designed to provide an affirmative defense against allegations of insider trading by allowing executives to sell shares at predetermined times and prices. This filing indicates routine portfolio management by a key executive.

Stakeholder Impact

• Shareholders: The sale of shares by an executive may be observed, but the execution under a Rule 10b5-1 plan suggests a pre-planned divestment rather than a reaction to non-public information.

Key Dates

Keywords

Core Scientific, CORZ, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beneficial Ownership, Todd DuChene